New prescriptions for Wegovy among teenagers increased by 50% between 2023 and 2024, according to a June 3 report from healthcare data company Truveta.
To analyze GLP-1 utilization trends among adolescents, Truveta examined data from 1.2 million children aged 12 to 17 who had a recorded body mass index the same day as an outpatient visit between Jan. 1, 2021, and March 31, 2025.
Fewer than 1% of adolescents in the study received a prescription for Wegovy or Saxenda, both weight loss drugs manufactured by Novo Nordisk. In 2023, the rate of first-time Wegovy prescriptions was 9.9 per 100,000 adolescents. That figure rose to 14.8 per 100,000 in 2024 — a 50% increase. First-time Saxenda prescriptions remained relatively stable, according to the report.
Wegovy prescription rates surged at a rate 17.7 times higher than Saxenda.
A separate report from Evernorth found even higher utilization rates among younger patients. Among adolescents prescribed GLP-1s for weight loss, Generation Alpha (ages 14 and younger) saw the steepest increase — 84.6% between 2023 and 2024. Generation Z (ages 15 to 28) followed with a 67.8% increase, while millennials (ages 29 to 43) experienced a 47.7% rise.
Health experts have told Becker’s that factors contributing to this trend include rising obesity rates and endorsements from social media influencers and celebrities.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
